Summit Therapeutics (SMMT) shares were higher premarket Wednesday after the company said that a phase 3 trial conducted by Akeso in China found that combining ivonescimab with chemotherapy demonstrated a clinically meaningful benefit compared with a tislelizumab-based regimen in patients with advanced squamous non-small cell lung cancer.
The HARMONi-6 phase 3 study reached a primary endpoint of improving progression-free survival, based on an interim analysis by an independent committee, Summit said.
The benefit was seen regardless of whether patients had PD-L1-positive or negative tumors, and no unexpected safety issues were observed, the company said.
Summit also said this is the second late-stage trial in which an ivonescimab-based therapy has demonstrated a significant advantage over a PD-L1-based standard treatment.
The company said it is running HARMONi-3, a phase 3 study comparing ivonescimab plus chemotherapy against pembrolizumab with chemotherapy for newly diagnosed metastatic patients with NSCLC.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.